FDA Approves VABRINTY — URONOVA PHARMACEUTICALS, INC.

# FDA Approves VABRINTY (Leuprolide Acetate) for Subcutaneous Administration Uronova Pharmaceuticals, Inc. received FDA approval for VABRINTY (leuprolide acetate) injection, expanding the company's portfolio in the hormonal therapy market and positioning it to capture market share in the treatment of prostate cancer and endometriosis. The subcutaneous formulation offers healthcare providers an additional delivery option in the established leuprolide market, which faces competitive pressure from generic alternatives and newer therapeutics.